Release Date: November 30, 2012
Expiration Date: November 30, 2013
Estimated Time to Complete Activity: 1.0 hour
Click Here to Claim Credit
CME ACCREDITATION AND DESIGNATION
||In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME: NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE: This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-12-040-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Director, Accreditation Services, NACCME, may be made for a second level of review.
CNE: This continuing nursing education activity awards 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.
AHRA Accreditation: Approved for 1 ARRT Category A CE credit by AHRA.
Independent Clinical Reviewer: Paul P. Dobesh, PharmD, FCCP, BCPS (AQ Cardiology), Associate Professor of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska
Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California
Planning Committee: The planning committee comprises Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, David J. Cohen, MD, MSc, Paul P. Dobesh, PharmD, FCCP, BCPS (AQ Cardiology), E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI, Philippe Gabriel Steg, MD, and Susie Seaman, NP; and Kristin Ciszeski, Stephen Chavez, Mary Johnson, Michael Kearney, Randy Robbin, and John Savage, NACCME.
This on-demand webcast is available with synchronized slides and audio.
To be eligible for documentation of credit, participants must complete the educational activity, complete the 20-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
There is no fee associated with this activity.
This educational activity is a knowledge-based activity.
For questions regarding this educational activity, please call 609-371-1137.
After completing this activity, participants should be able to:
- Outline new guidelines on acute coronary syndromes (ACS) management which incorporate newer antiplatelet agents and evidence
- Describe the benefi ts and limitations of available antiplatelet therapies, including risk of major bleeding, genetic factors, and reversibility
- Discuss the potential role of platelet reactivity testing and point-of-care genetic testing for ensuring optimal antiplatelet therapy
- Employ guideline-directed and evidence-based peri- and post-procedural antiplatelet strategies to reduce the risk of adverse cardiovascular events in ACS patients
This activity is designed for interventional cardiologists, clinical cardiologists, radiologists, basic scientists, vascular medicine specialists, surgeons, nurses, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.
Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The planning committee comprises Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, David J. Cohen, MD, MSc, Paul P. Dobesh, PharmD, FCCP, BCPS (AQ Cardiology), E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI, Philippe Gabriel Steg, MD, and Susie Seaman, NP; and Kristin Ciszeski, Stephen Chavez, Mary Johnson, Michael Kearney, Randy Robbin, and John Savage, NACCME.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Professor of Medicine, Harvard Medical School
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital & VA Boston Healthcare System
Senior Investigator, TIMI Study Group
David J. Cohen, MD, MSc
Director of Cardiovascular Research
Saint Luke’s Mid America Heart Institute
Missouri Endowed Professor of
Kansas City, Missouri
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
Duke Heart Center-Ambulatory Care
Director, Program for Advanced Coronary Disease
Duke University Medical Center
Durham, North Carolina
Philippe Gabriel Steg, MD
Professor of Cardiology
Department of Cardiology
Hôpital Bichat-Claude Bernard
Assistance Publique – Hôpitaux de Paris
FACULTY DISCLOSURE SUMMARY
The faculty has reported the following:
Dr. Bhatt: Grant/research support—Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, sanofi aventis, The Medicines Company
Dr. Cohen: Advisory board—AstraZeneca, Eli Lilly and Company, Merck and Co., Inc.; Grant/research support—AstraZeneca, Eli Lilly and Company
Dr. Dobesh: Consultant—Janssen Pharmaceuticals
Dr. Ohman: Grant/research support—Daiichi Sankyo, Eli Lilly and Company, Gilead Sciences; Consultant—AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals (Johnson & Johnson), Liposcience, Merck and Co., Inc., Pozen, Inc, Roche Diagnostics, sanofi aventis, The Medicines Company, WebMD
Ms. Seaman: Scientific advisor—Molnlycke; Promotional speakers bureau—Molnlycke
Dr. Steg: Grant/research support—NYU School of Medicine, sanofi aventis, Servier; Consultant/advisory board—Ablynx, Amarin, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, MSD, Novartis, Otsuka, Pfizer, Roche Diagnostics, sanofi aventis, Servier, The Medicines Company; Stockholder—Aterovax
Mr. Chavez, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty has disclosed that their presentations will include no discussion of investigative or off-label uses of any drugs or devices.
SPONSORSHIP AND SUPPORT
Supported by an educational grant from AstraZeneca.
MINIMUM SYSTEM REQUIREMENTS
All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to email@example.com.